

# Error Introduced into 16S rRNA Gene Sequencing Results Varies by High Fidelity DNA Polymerase Used

Marc A Sze<sup>1</sup> and Patrick D Schloss<sup>1†</sup>

† To whom correspondence should be addressed: [pschloss@umich.edu](mailto:pschloss@umich.edu)

<sup>1</sup> Department of Microbiology and Immunology, University of Michigan, Ann Arbor, MI

Co-author e-mails:

- [marcsze@med.umich.edu](mailto:marcsze@med.umich.edu)

## Abstract

**Background.** It is challenging to compare 16S rRNA gene sequencing data across studies and one of the reasons for this is due to error. There are many different places throughout the workflow where error can be introduced into the pipeline. Here, we focus on studying how the number of cycles and high fidelity (HiFi) DNA polymerase introduce error by varying cycle number and polymerase used to amplify 16S rRNA genes in human fecal and mock community samples.

**Methods.** We extracted DNA from fecal samples (n=4) using a PowerMag DNA extraction kit with a 10 minute bead beating step and amplified at 15, 20, 25, 30, and 35 cycles using Accuprime, Kappa, Phusion, Platinum, or Q5 HiFi DNA polymerase. Amplification of mock communities (technical replicates n=4) consisting of previously isolated whole genomes of 8 different bacteria used the same approach. The analysis initially examined the number of Operational Taxonomic Units (OTUs) for fecal samples and mock communities. It also assessed polymerase dependent differences in the Bray-Curtis index, error rate, sequence error prevalence, chimera prevalence, and the correlation between chimera prevalence and number of OTUs.

**Results.** When analyzing fecal samples we observed that the range in the number of OTUs detected was not consistent between HiFi DNA polymerases at 35 cycles (Accuprime = 84 - 106 (min - max) versus Phusion = 84 - 136). Additionally, the median number of OTUs varied by HiFi DNA polymerase used (P-value < 0.0001). When analyzing mock community samples the variation in the number of OTUs detected by the polymerases was observable as early as 20 cycles (P-value = 0.002). There also was a large range in the number of OTUs amplified by the polymerases at 35 cycles (Accuprime = 15 - 20 versus Phusion = 14 - 73). Chimera prevalence in mock communities varied by polymerase with differences being most notable at 35 cycles (Kappa = 5.71% (median) versus Platinum = 26.62%) and this variation persisted after chimera removal using VSEARCH. We also observed positive correlations between chimera prevalence and the number of OTUs with Platinum having the highest ( $R^2 = 0.974$ ) and Kappa having the worst ( $R^2 = 0.478$ ).

**Conclusions.** Although the variation in the number of OTUs in fecal samples could be due to certain polymerases capturing the biological variability better than others, this is unlikely to be the

28 main reason for our observed differences. In mock community samples, the strong correlation  
29 between chimera prevalence and the number of OTUs suggests that this is the main reason for  
30 differences between the polymerases. Ultimately, this variation makes comparison across studies  
31 difficult and care should be exercised when choosing the polymerase and number of cycles in 16S  
32 rRNA gene sequencing studies.

## 33 Introduction

34 The bacterial community is reported to vary between case and control for a number of diseases  
35 (Turnbaugh et al., 2008; Sze et al., 2015; Baxter et al., 2016; Bonfili et al., 2017). However, for  
36 diseases like obesity, the taxa identified have varied widely depending on the study (Turnbaugh  
37 et al., 2008; Zupancic et al., 2012). Some of this variation could be due to error introduced  
38 during the 16S rRNA gene sequencing workflow. Yet, standardizing a 16S rRNA gene sequencing  
39 workflow will ultimately result in a standardized and reproducible bias due to choices made on the  
40 methods used for preservation, extraction, PCR, and sequencing. Within this context, all 16S rRNA  
41 gene sequencing methods are biased even when these workflows are standardized to increase  
42 reproducibility. In order to interpret specific studies within the broader context of the overall field,  
43 assessing error at different parts of the 16S rRNA gene sequencing workflow is critical.

44 A typical 16S rRNA gene sequencing workflow can be divided into preservation, extraction, PCR,  
45 and sequencing steps. The preservation and extraction stages of the 16S rRNA gene sequencing  
46 workflow have been the most extensively studied (Salter et al., 2014; Song et al., 2016; Bassis et  
47 al., 2017; Kim et al., 2017). For preservation and extraction stages of the workflow, it has been  
48 consistently found that there are biases based on the kits used, but that these differences are  
49 smaller than the overall biological difference measured between samples with different kits (Song  
50 et al., 2016; Bassis et al., 2017). Since these studies use the same PCR approach while varying  
51 preservation or extraction method, the contribution of PCR bias to this overall workflow is not well  
52 characterized.

53 There is a large body of literature that shows there are biases due to primer and number of  
54 cycles chosen for the PCR stage of 16S rRNA gene sequencing (Eckert & Kunkel, 1991; Burkardt,  
55 2000). Primers have variable region dependent binding affinities which causes an inability to detect  
56 specific bacteria (e.g. V1-V3 does not detect *Haemophilus influenzae* and V3-V5 does not detect  
57 *Propionibacterium acnes*) (Sze et al., 2015 (Table S4); Meisel et al., 2016). Another source of error  
58 is the selective amplification of AT-rich over GC-rich sequences which exaggerate the difference  
59 between 16S rRNA genes higher in AT versus those higher in GC content (Polz & Cavanaugh,  
60 1998). Many of these sources of biases are made worse as the number of cycles increases (Wang &

Wang, 1996; Haas et al., 2011; Kebschull & Zador, 2015). For example, both amplification error and non-specific amplification (e.g. incorrect amplicon size products) also can increase as the number of cycles increases. This will increase the number of Operational Taxonomic Units (OTUs) observed and drastically change the values obtained from commonly used diversity measures (Acinas et al., 2005; Santos et al., 2016). Additionally, as the number of cycles increases more chimeras can form from an aborted extension step that causes a priming error and subsequent secondary extension (Haas et al., 2011). These chimeras will artificially increase community diversity by increasing the number of OTUs that are observed (Haas et al., 2011). In addition to these sources of errors, there also are multiple families of DNA polymerases that have their own error rate and proof reading capacity (Ishino & Ishino, 2014). Interestingly, the influence that these different DNA polymerases can have on the observed 16S rRNA gene sequencing results have not been well studied like some of the other sources of PCR-based bias.

A recent study found differences in the number of OTUS and chimeras between normal and high fidelity DNA polymerases (Gohl et al., 2016). The authors could reduce the difference between the two polymerases by optimizing the annealing and extension steps within the PCR protocol (Gohl et al., 2016). Yet, within this study there was no comparison made between different high fidelity DNA polymerases. Due to this gap, it is natural to extend this line of inquiry and test if biases in the number of OTUs and chimeras also are dependent on the type of high fidelity DNA polymerase. This study will investigate how high fidelity DNA polymerases can bias observed bacterial community results derived from 16S rRNA gene sequencing. We will accomplish this by examining the number of OTUs, error rate, number of sequences with an error, and chimera prevalence at varying number of cycles in five different high fidelity DNA polymerases

## Materials & Methods

**Human and Mock Samples:** Fecal samples were obtained from 4 individuals who were part of the Enterics Research Investigational Network (ERIN). The processing and storage of these samples were previously published (Seekatz et al., 2016). Other than confirmation that none of these individuals had a *Clostridium difficile* infection, clinical data and other types of meta data were not utilized or accessed for this study. All samples were extracted using the MOBIO™ PowerMag Microbiome RNA/DNA extraction kit (now Qiagen, MD, USA). The ZymoBIOMICS™ Microbial Community DNA Standard (Zymo, CA, USA) was used for mock communities and was made up of *Pseudomonas aeruginosa*, *Escherichia coli*, *Salmonella enterica*, *Lactobacillus fermentum*, *Enterococcus faecalis*, *Staphylococcus aureus*, *Listeria monocytogenes*, and *Bacillus subtilis* at equal genomic DNA abundance (<http://www.zymoresearch.com/microbiomics/microbial-standards/zymbiomics-microbial-community-standards>).

**PCR Protocol:** The five different high fidelity DNA polymerases (hereto referred to as polymerases) that were tested included AccuPrime™ (ThermoFisher, MA, USA), KAPA HIFI (Roche, IN, USA), Phusion (ThermoFisher, MA, USA), Platinum (ThermoFisher, MA, USA), and Q5 (New England Biolabs, MA, USA). The polymerases activation time was 2 minutes, unless a different activation was specified by the manufacturer. The annealing and extension time for Platinum and Accuprime followed a previously published protocol (Kozich et al., 2013) ([https://github.com/SchlossLab/MiSeq\\_WetLab\\_SOP/blob/master/MiSeq\\_WetLab\\_SOP\\_v4.md](https://github.com/SchlossLab/MiSeq_WetLab_SOP/blob/master/MiSeq_WetLab_SOP_v4.md)). For Kappa and Q5, the annealing and extension time were from a previously published protocol (Gohl et al., 2016). For Phusion, the company defined activation and annealing times were used while the extension time followed the Accuprime and Platinum settings.

The number of cycles in the PCR for fecal and mock samples started at 15 and increased by 5 up to 35 cycles, with amplicons used at each 5-step increase for sequencing. The PCR of fecal DNA samples consisted of all 4 samples at 15, 20, 25, 30, and 35 cycles for each polymerase (total sample n=100). The mock communities had 4 replicates at 15, 20, 25, and 35 cycles and 10 replicates for 30 cycles for all polymerases (total samples n=130). No mock community sample had enough PCR product at 15 cycles for adequate 16S rRNA gene sequencing.

**Sequence Processing:** The mothur software program was used for all sequence processing steps (Schloss et al., 2009). The protocol has been previously published (Kozich et al., 2013) ([https://www.mothur.org/wiki/MiSeq\\_SOP](https://www.mothur.org/wiki/MiSeq_SOP)). Two major differences from the published protocol were the use of VSEARCH instead of UCHIME for chimera detection and the use of the OptiClust algorithm instead of average neighbor for OTU generation at 97% similarity (Edgar et al., 2011; Rognes et al., 2016; Westcott & Schloss, 2017). Sequence error was determined using the 'seq.error' command on mock samples to compare back to the reference 16S sequences (Schloss et al., 2009; Cole et al., 2013; Rognes et al., 2016).

**Analysis Workflow:** To adjust for unequal sequencing, all samples were rarefied to 1000 sequences for downstream analysis. The total number of OTUs was analyzed for both the fecal and mock community samples. For fecal samples, cycle dependent affects on Bray-Curtis indices were assessed for cycle group and within individual differences from the previous cycle (e.g. 20 versus 25, 25 versus 30). Based on these observations we analyzed potential reasons for these differences. Analysis of the mock community of each polymerase for sequence error rate, number of sequences with an error, base substitution, and numbers of chimeras before and after chimera removal with VSEARCH was assessed. Additionally, the correlation between the number of chimeras and the number of OTUs was also assessed.

**Statistical Analysis:** All analysis was done with the R (v 3.4.4) software package (R Core Team, 2017). Data transformation and graphing was completed using the tidyverse package (v 1.2.1) and colors selected using the viridis package (v 0.4.1) (Garnier, 2017; Wickham, 2017). Differences in the total number of OTUs were analyzed using an ANOVA with a tukey post-hoc test. For the fecal samples the data was normalized to each individual by cycle number to account for the biological variation between people. Bray-Curtis distance matrices were generated using mothur after 100 sub-samplings at 1000, 5000, 10000, and 15000 sequence depth. The distance matrix data was analyzed using PERMANOVA with the vegan package (v 2.4.5) (Oksanen et al., 2017) and Kruskal-Wallis tests within R. For both error and chimera analysis, samples were tested using Kruskal-Wallis with a Dunns post-hoc test. Where applicable correction for multiple comparison utilized the Benjamini-Hochberg method (Benjamini & Hochberg, 1995).

139 ***Reproducible Methods:*** The code and analysis can be found here [https://github.com/SchlossLab/](https://github.com/SchlossLab/Size_PCRSeqEffects_XXXX_2017)  
140 [Size\\_PCRSeqEffects\\_XXXX\\_2017](https://github.com/SchlossLab/Size_PCRSeqEffects_XXXX_2017). The raw sequences can be found in the SRA at the following  
141 accession number SRP132931.



## Results

***The number of OTUs generated are dependent on polymerase used:*** Differences in the range of the number of OTUs detected for fecal samples is dependent on the polymerase used (e.g. Accuprime at 35 cycles = 84 - 106 versus Phusion at 35 cycles = 84 - 136) [Figure 1]. Additionally, there is a trend for lower number of cycles (15-20) to result in a reduced range in the number of OTUs versus higher number of cycles (25, 30, and 35) for all polymerases (e.g. Phusion at 15 cycles = 10 - 19 versus Phusion at 35 cycles = 84 - 136) [Figure 1]. There is an overall difference in the number of OTUs detected within fecal samples between polymerases at 35 cycles (F-stat > 16.35, P-value = 9.7e-05) [Table S1]. Using a Tukey post-hoc test to identify which polymerase groups were different from each other at 35 cycles, no difference was found (P-value > 0.05) [Table S2]. The polymerase dependent difference in the range of the number of OTUs also was observed in the mock community samples [Figure 2]. The closest the polymerases came to the total of 8 OTUs created by the mock reference 16S sequences was at 25 and 30 cycles [Figure 2]. Regardless of if fecal or mock communities were used, the same polymerases generated high and low number of OTUs and this was consistent across the number of cycles used [Figure 1-2 & Table S1-S2]. In contrast to the results obtained with fecal samples, differences between polymerases for the number of OTUs created were observed as early as 20 cycles in the mock community (F-stat = 15.82, P-value = 0.002) [Table S1]. Using a Tukey post-hoc test, the majority of differences for the number of OTUs detected in the mock community is largely due to Kappa and Platinum differences versus the other polymerases across the different number of cycles [Table S2]. Based on these observations in fecal and mock communities, it is clear that using different polymerases result in a different total number of OTUs within a sample.

***The bacterial community is similar within polymerase and varies by number of cycles:***

Within each respective 5-cycle increment comparison there was no difference in Bray-Curtis index between the polymerases (P-value > 0.05) [Figure 3]. Using PERMANOVA to test for community differences based on any of the number of cycles within polymerases, only Phusion had cycle dependent differences (P-value = 0.03. For fecal samples, Phusion was one of two polymerases that had enough sequences to be rarefied to 1000 at 15 cycles. There was an overall decrease in

Bray-Curtis index by cycle comparison group (e.g. the 15 cycle versus 20 cycle group compared to the 30 cycle to 35 cycle group) (P-value < 0.01) [Figure 3A]. Using a Dunn's post-hoc test the 15 cycle versus 20 cycle and 20 cycle versus 25 cycle comparison groups had a higher Bray-Curtis index than the 30 cycle versus 35 cycle comparison group < 0.05). The mock community has similar trends to the observations reported for the fecal bacterial community but none were significant > 0.05) [Figure 3B]. Overall, these data suggest that the number of cycles can change the bacterial community independent of the polymerase used to generate the sequences.

***Sequence error varies by polymerase and is consistent across the number of cycles used:***

The median error rate varied by polymerase, with Kappa having the highest error rate of all the polymerases across the number of cycles [Figure 4 & Table S3]. The majority of the differences across the number of cycles was between Kappa and the other polymerases [Figure 4 and Table S4]. The total sequences with at least one error is also polymerase dependent with the majority of differences being between Kappa or Accuprime and the other polymerases [Table S3 & S4]. These differences in error rates were not due to polymerase dependent differences in base substitution rate [Figure S1]. Collectively, the results suggest that sequence error is dependent on polymerase, persists across the number of cycles used, and are not due to any bias towards a specific base substitution.

***Prevalence of chimeric sequences are polymerase dependent and correlate with the***

***number of OTUs:*** Based on the previous results, we examined whether chimeras also were dependent on polymerase and whether this could affect the number of OTUs. We observed significant differences in the chimera prevalence based on polymerase across the number of cycles used (P-value < 0.05) [Table S3]. Differences in chimera prevalence between Platinum and all other polymerases accounted for the majority of these differences [Table S4]. Accuprime™ had the lowest chimera prevalence of all polymerases regardless of whether chimera removal with VSEARCH was used [Figure 5A & 5B]. The number of cycles used clearly increased chimera prevalence for all polymerases but the rate of increase differed [Figure 5A & 5B]. Additionally, there was a plateau in the total percent of chimeras that were removed that was similar for all polymerases [Figure 5C]. A positive correlation was observed between chimeric sequences and the number of OTUs for all polymerases [Figure 6]. This positive correlation was strongest for

199 Accuprime™, Platinum, and Phusion [Figure 6]. This data suggests that chimera prevalence  
200 depends on polymerase, is made worse by increasing the number of cycles, and confirms that the  
201 number of OTUs is dependent on the prevalence of these chimeric sequences.

## Discussion

Our observations support that the number of OTUs, error rate, and chimera prevalence depends on polymerase used and that chimera prevalence is highly correlated with the number of OTUs [Figure 1-2 & 4-6]. Our observations also suggest that undetected chimeras, not removed using standard bioinformatic approaches, cause many of these differences. In addition to the reported polymerase dependent differences, the bacterial community also varied by the number of cycles used. These differences are important because many diversity metrics rely on calculations (e.g. richness) that are dependent on the number of OTUs. Since the number of OTUs are dependent on error rate and chimera prevalence the diversity metrics can vary simply by changing the polymerase used. Based on these observations, metrics that measure diversity using calculations such as richness depend on the polymerase, but this may not be the case for all diversity metrics.

Based on polymerase used, our observations generally found no difference when using the Bray-Curtis index to measure the bacterial community. Specifically, there was no difference in distance between successive 5-cycle increments within samples between the polymerases when using the Bray-Curtis index [Figure 3]. However, the distance between cycle comparison groups (e.g. 20 cycles versus 25 cycles group compared to 30 cycles versus 35 cycles group) was different across polymerase used. These results support the idea that cycle number and not the specific polymerase used may have a larger affect on metrics such as Bray-Curtis. One possible reason for this outcome is that many of the OTUs generated by polymerase dependent error rates and chimera prevalence are likely not highly abundant, allowing the Bray-Curtis index to be able to successfully down-weight these OTUs (Minchin, 1987). The choice of downstream diversity metric could be an important consideration in helping to mitigate some of the observed polymerase dependent differences in error rate and chimera prevalence. Metrics that solely use presence/absence of OTUs (e.g. Jaccard (Real & Vargas, 1996), richness) may be less robust to polymerase dependent error rates and chimera prevalence. When choosing a distance metric, careful consideration of the biases introduced from the PCR step of the 16S rRNA gene sequencing workflow need to be taken into account. One possible way to better choose polymerases may be based on the DNA polymerase family used in the PCR mixture.

Although the variation in error rate and chimera prevalence may be due to the DNA polymerase family because of the different binding affinities and error correction capacity (Ishino & Ishino, 2014), this is unlikely to be the only contributor. Within our study the highest and lowest chimera prevalence both belonged to a family A polymerase (Platinum and Accuprime<sup>TM</sup> respectively) (Ishino & Ishino, 2014). Additionally, based on the information supplied by the respective manufacturers, the differences between the two PCR mixtures are not immediately apparent. Both PCR mixtures contain a recombinant *Taq* DNA polymerase, a *Pyrococcus* spp GB-D polymerase and a platinum *Taq* antibody. Since it is not possible to know everything about the mixture beyond what was willingly provided by the manufacturer, it is possible that differences in how the recombinant *Taq* was generated or other compounds within the PCR mixture could be a contributing factor for the differences in error rate and chimera prevalence. Beyond the choice of the type of polymerase, there may be other ways to reduce the affect of polymerase dependent error rates and chimera prevalence on the downstream results.

Standardization of the 16S rRNA gene sequencing workflow may partially solve this problem by introducing a consistent bias to all samples. However, as mentioned in the introduction, many of the choices made to standardize the workflow will result in missing important members of the microbial community. Therefore, the degree of workflow standardization across studies and research groups need to be approached on a study by study basis. All aspects of the 16S rRNA gene sequencing workflow should be customized for the specific scientific questions that wants to be answered. Although a diversity of approaches may make reproducibility and replicability more difficult it will help reduce systematic biases from occuring.

## 251 **Conclusion**

252 Our observations fill a gap in knowledge on the bias introduced to 16S rRNA gene sequencing  
253 results due to differences in polymerases. We found that the number of OTUs and the chimera  
254 prevalence is dependent on both polymerase and cycle number chosen. Care should be taken when  
255 choosing a polymerase for 16S rRNA gene surveys because their intrinsic differences can change  
256 the number of OTUs observed and influence diversity based metrics that do not down-weight rare  
257 observations. Knowing the inherent bias associated with different polymerases allows for better  
258 interpretation of the relationship between an individual study to their respective field of research.

## Acknowledgements

The authors would like to thank all the study participants in ERIN whose samples were utilized. We would also like to thank Judy Opp and April Cockburn for their effort in sequencing the samples as part of the Microbiome Core Facility at the University of Michigan. Salary support for Marc A. Sze came from the Canadian Institute of Health Research and NIH grant UL1TR002240. Salary support for Patrick D. Schloss came from NIH grants P30DK034933 and 1R01CA215574.

## References

- Acinas SG., Sarma-Rupavtarm R., Klepac-Ceraj V., Polz MF. 2005. PCR-induced sequence artifacts and bias: Insights from comparison of two 16S rRNA clone libraries constructed from the same sample. *Applied and Environmental Microbiology* 71:8966–8969. DOI: 10.1128/aem.71.12.8966-8969.2005.
- Bassis CM., Nicholas M. Moore., Lolans K., Seekatz AM., Weinstein RA., Young VB., Hayden MK. 2017. Comparison of stool versus rectal swab samples and storage conditions on bacterial community profiles. *BMC Microbiology* 17. DOI: 10.1186/s12866-017-0983-9.
- Baxter NT., Ruffin MT., Rogers MAM., Schloss PD. 2016. Microbiota-based model improves the sensitivity of fecal immunochemical test for detecting colonic lesions. *Genome Medicine* 8. DOI: 10.1186/s13073-016-0290-3.
- Benjamini Y., Hochberg Y. 1995. Controlling the false discovery rate: A practical and powerful approach to multiple testing. *Journal of the Royal Statistical Society. Series B (Methodological)* 57:289–300.
- Bonfili L., Cekarini V., Berardi S., Scarpona S., Suchodolski JS., Nasuti C., Fiorini D., Boarelli MC., Rossi G., Eleuteri AM. 2017. Microbiota modulation counteracts alzheimer's disease progression influencing neuronal proteolysis and gut hormones plasma levels. *Scientific Reports* 7. DOI: 10.1038/s41598-017-02587-2.
- Burkardt H-J. 2000. Standardization and quality control of PCR analyses. *Clinical Chemistry and Laboratory Medicine* 38. DOI: 10.1515/cclm.2000.014.
- Cole JR., Wang Q., Fish JA., Chai B., McGarrell DM., Sun Y., Brown CT., Porras-Alfaro A., Kuske CR., Tiedje JM. 2013. Ribosomal database project: Data and tools for high throughput rRNA analysis. *Nucleic Acids Research* 42:D633–D642. DOI: 10.1093/nar/gkt1244.
- Eckert KA., Kunkel TA. 1991. DNA polymerase fidelity and the polymerase chain reaction. *Genome*



289 *Research* 1:17–24. DOI: 10.1101/gr.1.1.17.

290 Edgar RC., Haas BJ., Clemente JC., Quince C., Knight R. 2011. UCHIME improves sensitivity and  
291 speed of chimera detection. *Bioinformatics* 27:2194–2200. DOI: 10.1093/bioinformatics/btr381.

292 Garnier S. 2017. *Viridis: Default color maps from 'matplotlib'*.

293 Gohl DM., Vangay P., Garbe J., MacLean A., Hauge A., Becker A., Gould TJ., Clayton JB., Johnson  
294 TJ., Hunter R., Knights D., Beckman KB. 2016. Systematic improvement of amplicon marker gene  
295 methods for increased accuracy in microbiome studies. *Nature Biotechnology* 34:942–949. DOI:  
296 10.1038/nbt.3601.

297 Haas BJ., Gevers D., Earl AM., Feldgarden M., Ward DV., Giannoukos G., Ciulla D., Tabbaa D.,  
298 Highlander SK., Sodergren E., Methe B., DeSantis TZ., Petrosino JF., Knight R., and BWB. 2011.  
299 Chimeric 16S rRNA sequence formation and detection in sanger and 454-pyrosequenced PCR  
300 amplicons. *Genome Research* 21:494–504. DOI: 10.1101/gr.112730.110.

301 Ishino S., Ishino Y. 2014. DNA polymerases as useful reagents for biotechnology â the history of  
302 developmental research in the field. *Frontiers in Microbiology* 5. DOI: 10.3389/fmicb.2014.00465.

303 Kobschull JM., Zador AM. 2015. Sources of PCR-induced distortions in high-throughput sequencing  
304 data sets. *Nucleic Acids Research*:gkv717. DOI: 10.1093/nar/gkv717.

305 Kim D., Hofstaedter CE., Zhao C., Mattei L., Tanes C., Clarke E., Lauder A., Sherrill-Mix S.,  
306 Chehoud C., Kelsen J., Conrad M., Collman RG., Baldassano R., Bushman FD., Bittinger K.  
307 2017. Optimizing methods and dodging pitfalls in microbiome research. *Microbiome* 5. DOI:  
308 10.1186/s40168-017-0267-5.

309 Kozich JJ., Westcott SL., Baxter NT., Highlander SK., Schloss PD. 2013. Development of a  
310 dual-index sequencing strategy and curation pipeline for analyzing amplicon sequence data on the  
311 MiSeq illumina sequencing platform. *Applied and Environmental Microbiology* 79:5112–5120. DOI:  
312 10.1128/aem.01043-13.

313 Meisel JS., Hannigan GD., Tyldsley AS., SanMiguel AJ., Hodkinson BP., Zheng Q., Grice EA. 2016.

314 Skin microbiome surveys are strongly influenced by experimental design. *Journal of Investigative*  
315 *Dermatology* 136:947–956. DOI: 10.1016/j.jid.2016.01.016.

316 Minchin PR. 1987. An evaluation of the relative robustness of techniques for ecological ordination.  
317 *Vegetatio* 69:89–107. DOI: 10.1007/bf00038690.

318 Oksanen J., Blanchet FG., Friendly M., Kindt R., Legendre P., McGlinn D., Minchin PR., O'Hara  
319 RB., Simpson GL., Solymos P., Stevens MHH., Szoecs E., Wagner H. 2017. *Vegan: Community*  
320 *ecology package*.

321 Polz MF., Cavanaugh CM. 1998. Bias in template-to-product ratios in multitemplate PCR. *Applied*  
322 *and Environmental Microbiology* 64:3724–3730.

323 R Core Team. 2017. *R: A language and environment for statistical computing*. Vienna, Austria: R  
324 Foundation for Statistical Computing.

325 Real R., Vargas JM. 1996. The probabilistic basis of jaccards index of similarity. *Systematic Biology*  
326 45:380–385. DOI: 10.1093/sysbio/45.3.380.

327 Rognes T., Flouri T., Nichols B., Quince C., Mahé F. 2016. VSEARCH: A versatile open source tool  
328 for metagenomics. *PeerJ* 4:e2584. DOI: 10.7717/peerj.2584.

329 Salter SJ., Cox MJ., Turek EM., Calus ST., Cookson WO., Moffatt MF., Turner P., Parkhill J., Loman  
330 NJ., Walker AW. 2014. Reagent and laboratory contamination can critically impact sequence-based  
331 microbiome analyses. *BMC Biology* 12. DOI: 10.1186/s12915-014-0087-z.

332 Santos QMB-d los., Schroeder JL., Blakemore O., Moses J., Haffey M., Sloan W., Pinto AJ.  
333 2016. The impact of sampling, PCR, and sequencing replication on discerning changes in  
334 drinking water bacterial community over diurnal time-scales. *Water Research* 90:216–224. DOI:  
335 10.1016/j.watres.2015.12.010.

336 Schloss PD., Westcott SL., Ryabin T., Hall JR., Hartmann M., Hollister EB., Lesniewski RA.,  
337 Oakley BB., Parks DH., Robinson CJ., Sahl JW., Stres B., Thallinger GG., Horn DJV., Weber CF.  
338 2009. Introducing mothur: Open-source, platform-independent, community-supported software

for describing and comparing microbial communities. *Applied and Environmental Microbiology* 75:7537–7541. DOI: 10.1128/aem.01541-09.

Seekatz AM., Rao K., Santhosh K., Young VB. 2016. Dynamics of the fecal microbiome in patients with recurrent and nonrecurrent clostridium difficile infection. *Genome Medicine* 8. DOI: 10.1186/s13073-016-0298-8.

Song SJ., Amir A., Metcalf JL., Amato KR., Xu ZZ., Humphrey G., Knight R. 2016. Preservation methods differ in fecal microbiome stability, affecting suitability for field studies. *mSystems* 1:e00021–16. DOI: 10.1128/msystems.00021-16.

Sze MA., Dimitriu PA., Suzuki M., McDonough JE., Campbell JD., Brothers JF., Erb-Downward JR., Huffnagle GB., Hayashi S., Elliott WM., Cooper J., Sin DD., Lenburg ME., Spira A., Mohn WW., Hogg JC. 2015. Host response to the lung microbiome in chronic obstructive pulmonary disease. *American Journal of Respiratory and Critical Care Medicine* 192:438–445. DOI: 10.1164/rccm.201502-0223oc.

Turnbaugh PJ., Hamady M., Yatsunenko T., Cantarel BL., Duncan A., Ley RE., Sogin ML., Jones WJ., Roe BA., Affourtit JP., Egholm M., Henrissat B., Heath AC., Knight R., Gordon JI. 2008. A core gut microbiome in obese and lean twins. *Nature* 457:480–484. DOI: 10.1038/nature07540.

Wang GCY., Wang Y. 1996. The frequency of chimeric molecules as a consequence of PCR co-amplification of 16S rRNA genes from different bacterial species. *Microbiology* 142:1107–1114. DOI: 10.1099/13500872-142-5-1107.

Westcott SL., Schloss PD. 2017. OptiClust, an improved method for assigning amplicon-based sequence data to operational taxonomic units. *mSphere* 2:e00073–17. DOI: 10.1128/mspheredirect.00073-17.

Wickham H. 2017. *Tidyverse: Easily install and load 'tidyverse' packages*.

Zupancic ML., Cantarel BL., Liu Z., Drabek EF., Ryan KA., Cirimotich S., Jones C., Knight R., Walters WA., Knights D., Mongodin EF., Horenstein RB., Mitchell BD., Steinle N., Snitker S., Shuldiner AR., Fraser CM. 2012. Analysis of the gut microbiota in the old order amish and its relation to the metabolic syndrome. *PLoS ONE* 7:e43052. DOI: 10.1371/journal.pone.0043052.

**Figure 1: Total Number of OTUs in Fecal Samples by Number of Cycles.** The points represent the median number of OTUs of all four fecal samples. The lines represent the range of the minimum and maximum number of OTUs detected within the four fecal samples. The range in the number of OTUs detected in the different fecal samples increased as cycle number increased. This increased range also was larger for specific HiFi DNA polymerases.

**Figure 2: Total Number of OTUs in Mock Samples by Number of Cycles.** The points represent the median number of OTUs for the mock samples. The lines represent the range of the minimum and maximum number of OTUs detected within the four fecal samples. The dotted black line represents the number of OTUs detected when only the references sequences for the mock community are clustered. The range in the number of OTUs detected in the mock samples increased as cycle number increased. This range was also larger for specific HiFi DNA polymerases.

**Figure 3: Bray-Curtis Community Differences by Five-Cycle Intervals.** A) within person differences based on the next 5-cycle PCR interval in fecal samples. B) Within replicate difference based on the next 5-cycle PCR interval in mock samples. The points represent the median Bray-Curtis index for the samples. The lines represent the range of the minimum and maximum Bray-Curtis index value for each PCR 5-cycle increment comparison. The closer a sample is to a Bray-Curtis index of 1.00 the more dissimilar the bacterial community is of the two compared number of cycles.

**Figure 4: HiFi DNA Polymerase Error Rate in Mock Samples.** The error bars represent the 75% interquartile range of the median error rate.

**Figure 5: HiFi DNA Polymerase Chimera Prevalence in Mock Samples.** A) Percentage of chimeric sequences without the removal of chimeras with VSEARCH. C) Percentage of chimeric sequences with the removal of chimeras with VSEARCH. C) The total percent of chimeric sequences removed with VSEARCH by cycle number. The error bars represent the 75% interquartile range of the median.

**Figure 6: The Correlation between Number of OTUs and Chimeras in Mock Samples.**

391 **Figure S1: HiFi DNA Polymerase Nucleotide Substitutions in Mock Samples.**